Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Journal of Orthopaedic Surgery and Research

Fig. 2

From: Exosomal Manf originated from endothelium regulated osteoclast differentiation by down-regulating NF-κB signaling pathway

Fig. 2

HUVEC-exos inhibited osteoclast differentiation in vitro. A Representative images of PKH67 (green) and DAPI (Blue) immunostaining, scale bar = 100 nm. B Representative images of TRAP staining of RAW264.7 cells treated with RANKL or RANKL + HUVEC Exos in vitro, scale bar = 100 nm. C quantiative analysis of positive TRAP staining in Fig. 2B (*P < 0.05). D Expression levels of Ctsk and Nfatc1 in RAW264.7 cells treated with RANKL or RANKL + HUVEC Exos in vitro (*P < 0.05)

Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X